drugset

drugset / Trial / NCT01167335

Evaluate the Efficacy of BGG492 as Adjunctive Treatment in Patients With Refractory Partial Onset Seizures

NCT01167335 ↗

Phase 2 Withdrawn Novartis

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will assess the efficacy of BGG492 as adjunctive treatment in patients with refractory partial onset seizures

Timeline

Start: 2010-08
Primary completion: 2010-11
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	selurampanel	Small molecule	—	Oral

Indications